Home › NCT06975111
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Who can join
Ages 45 to 55 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * aged 45-55 * In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18 * No current use of hormone therapy or hormonal contraception * Presence of a uterus and at least one ovary in order to track menstrual patterns * Have a smartphone and broadband access adequate to accept telehealth appointments Exclusion Criteria: * Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth) * Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant. * Pregnancy or actively trying to get pregnant * Inability to adhere to study protocol schedule * Untreated alcoholism * Un- Diagnosed abnormal uterine bleeding * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\> 30 kg/m2.
About the study
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.
What is being tested
- Metformin (drug)
- semaglutide (drug)
- Anti-hypertensives (drug)
- Lipid Lowering Medication (drug)
- Life style intervention (behavioral)
- Fezolinetant (drug)
Sponsor: University of Colorado, Denver · Participants: 200 · Started: Mar 1, 2026
Contact the study team
- Carrie Hsu, BA · Phone: 303-724-5276
Official record on ClinicalTrials.gov — NCT06975111
Locations in the U.S.
| Colorado | University of Colorado-School of Medicine, Aurora |
| North Carolina | University of North Carolina, School of Medicine, Chapel Hill |
| Virginia | Virginia Commonwealth University, Richmond |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.